Phase 1/2Recruiting
A Platform Study in Non-Small Cell Lung Cancer (NSCLC) (ALTAIR)
A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer
- Sponsor
- AstraZeneca (Industry)
- Enrolment
- 152 planned
- Conditions
- Advanced or Metastatic Non-small Cell Lung Cancer
- Interventions
- Rilvegostomig; Cisplatin; Carboplatin; Pemetrexed; Paclitaxel; Nab-paclitaxel; Ramucirumab
- Ages
- adults, older adults
- Registry
- NCT06996782
From the registry
The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC.
Primary outcomes
- Part A and Part B: Number of participants with adverse events (AEs) and serious adverse events (SAEs)
- Part A: Number of partcipants with dose limiting toxicity (DLT)
- Part B: Objective response (OR)